Table 3

Potential for confounding by indication; predicted percentage with adverse events within 5 years, and treatment outcome after 1 year, based on observed baseline characteristics

CohortAll-cause mortalityMalignancyMACESerious infectionDrug survival <1 yearGood EULAR response at 1 year
First bDMARDCrudeSTDCrudeSTDCrudeSTDCrudeSTDCrudeSTDCrudeSTD
Switch from TNFi
  • Predicted observed percentage (crude) and age-sex standardised to TNFi as first bDMARD (STD).

  • bDMARD, biological disease-modifying anti-rheumatic drug; EULAR, European League Against Rheumatism; MACE, major acute cardiovascular event; TNFi,  tumour necrosis factor inhibitor.